# Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia

> Research article (Cancer Discovery, 2023) · cited 89× · AI/ML

**Wikidata**: [openalex:W4388221408](https://www.wikidata.org/wiki/openalex:W4388221408)  
**Source**: https://4ort.xyz/entity/discovery-and-clinical-proof-of-concept-of-rly-2608-a-first-in-class-mutant-selective-allosteric-pi3k-inhibitor-that-dec